logo
Share SHARE
FONT-SIZE Plus   Neg

Roche, PTC Sign Deal To Advance Treatment For Spinal Muscular Atrophy

Roche Holding AG (RHHBY.PK), PTC Therapeutics, Inc. and the SMA Foundation, announced a licensing agreement for PTC's Spinal Muscular Atrophy, or SMA, programme. SMA is a genetic neuromuscular disorder that causes muscle weakness.

As per the terms of the agreement, Roche gains an exclusive worldwide license to PTC's SMA programme, which includes three compounds currently in preclinical development, as well as potential back-up compounds. PTC receives $30 million as an upfront payment, up to $460 million upon successful completion of certain development and commercialization milestones and up to double-digit royalties on commercial sales. PTC noted that development will be overseen by a joint steering committee comprised of members from Roche, PTC and the SMA Foundation.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Casino operator Wynn Resorts said its shareholders ousted Elaine Wynn from the board, reflecting fears that her presence may lead to disharmony with the management. To commemorate the launch of Hubble telescope twenty-five year ago, NASA unveiled celestial fireworks as official image, marked by brilliant tapestry of young stars flaring to life. Abercrombie & Fitch said it would stop hiring store employees based on their body type or physical attractiveness, and that its events, including store openings, will no longer have the presence of shirtless models.
comments powered by Disqus
Follow RTT